Mabwell (Shanghai) Bioscience Co., Ltd.

迈威(上海)生物科技股份有限公司

02493.HK

Develops and commercializes innovative drugs in China, focused on oncology, immunology, ophthalmology and orthopedics, with four commercialized products and a pipeline including the Nectin-4 targeting ADC 9MW2821 in Phase III trials.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Overlapping customers and suppliers
• Distribution model
• Reliance on platforms, partners or licences
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Particular sales arrangements
• Key long-term agreements
• Capacity and utilisation
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Goodwill, intangibles and asset impairment
• Indebtedness, guarantees and other contingent obligations
• Adverse change after the track record
• Related-party transactions and balances
• Chapter 18A biotech